Chronic Pain Market to Surpass US$ 108,814 Million by 2028 | Abbott Laboratories, AstraZeneca plc, Bristol-Myers Squibb Company, Becton.

The global chronic pain market is estimated to be valued at US$ 64,068 Mn in 2021 and is expected to exhibit a CAGR of 6.9% over the forecast period (2021-2028).

Market Drivers

Development and launch of new drugs is expected to propel growth of the global chronic pain market over the forecast period. For instance, Daiichi Sankyo Company, Limited, in April 2019, launched Tarlige Tablets 2.5 mg, 5 mg, 10 mg, 15 mg (generic name: mirogabalin besilate; hereafter, the drug) for the treatment of pain in Japan.

Market Opportunities

R&D of new drugs is expected to offer lucrative growth opportunities for players in the global chronic pain market. For instance, Regeneron Pharmaceuticals, Inc. and Teva Pharmaceutical Industries Ltd., in August 2018, announced positive topline results from a Phase 3, randomized, double-blind, placebo-controlled study of fasinumab in patients with chronic pain from osteoarthritis (OA) of the knee or hip.

Click Here to Get a Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/4767

Market Trends

Major players operating in the global chronic pain market are focused on adopting partnership strategies to expand their product portfolio. For instance, Kineta Chronic Pain, LLC, in April 2018, partnered with Genentech, a member of the Roche Group, for the development of Kineta’s α9/α10 nicotinic acetylcholine receptor antagonists for the treatment of chronic pain.

Major players operating in the global chronic pain market are focused on approval and launch of new products to expand their product portfolio. For instance, AbbVie, in July 2018, in cooperation with Neurocrine Biosciences, Inc., received the U.S. Food and Drug Administration approval for ORILISSA (elagolix) the treatment of women with moderate to severe endometriosis pain

Covid-19 Impact Analysis

Globally, as of 5:20pm CET, 18 February 2022, there have been 418,650,474 confirmed cases of COVID-19, including 5,856,224 deaths, reported to WHO. As of 20 February 2022, a total of 10,407,359,583 vaccine doses have been administered. Chronic pain management during the COVID-19 pandemic has been a challenging task. Several studies have reported link between the infection and myalgias, referred pain, and widespread hyperalgesia. People suffering from COVID-19 have reported muscular pain, joint pain, stomach pain, testicular pain, and neuropathic pain. In such scenario, it is important to ensure the care continuity, painkillers, use of telemedicine, and a biopsychosocial management approach.

Key Players                                                         

Major players operating in the global chronic pain market include, Abbott Laboratories, AstraZeneca plc., Bristol-Myers Squibb Company, Becton, Dickinson and Company, Eli Lilly and Company, GlaxoSmithKline plc., Johnson & Johnson, Novartis AG, Pfizer Inc., and Sanofi S.A.

Key Developments                                             

Major players operating in the global chronic pain market are focused on approval and launch of new products to expand their product portfolio. For instance, the U.S. Food and Drug Administration, in August 2011, approved NUCYNTA ER, an oral analgesic taken twice daily from Janssen Pharmaceuticals, Inc., for the management of moderate to severe chronic pain in adults.

Major players operating in the global chronic pain market are also focused on adopting partnership strategies to expand their product portfolio. For instance, Grünenthal, in September 2019, partnered with UniQuest, a commercialization arm of University of Queensland, for R&D of non-opioid drug therapies derived from the group of alpha-conotoxins as analgesic and disease modifying treatments of chronic neuropathic pain.

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/4767

Table of Content

Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Chronic Pain Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Chronic Pain Industry Impact

Chapter 2 Global Chronic Pain Competition by Types, Applications, and Top Regions and Countries
2.1 Global Chronic Pain (Volume and Value) by Type
2.3 Global Chronic Pain (Volume and Value) by Regions

Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis

Chapter 4 Global Chronic Pain Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Chronic Pain Market Analysis
Chapter 6 East Asia Chronic Pain Market Analysis
Chapter 7 Europe Chronic Pain Market Analysis
Chapter 8 South Asia Chronic Pain Market Analysis
Chapter 9 Southeast Asia Chronic Pain Market Analysis
Chapter 10 Middle East Chronic Pain Market Analysis
Chapter 11 Africa Chronic Pain Market Analysis
Chapter 12 Oceania Chronic Pain Market Analysis
Chapter 13 South America Chronic Pain Market Analysis
Chapter 14 Company Profiles and Key Figures in Chronic Pain Business
Chapter 15 Global Chronic Pain Market Forecast (2022-2028)
Chapter 16 Conclusions
Research Methodology